Analytical Data
-
Gene name
Ki67/MKI67
- Application
-
Alternative Names
Antigen identified by monoclonal Ki 67 ; Antigen identified by monoclonal Ki-67; Antigen KI-67; Antigen KI67 ; Antigen Ki67; KI67_HUMAN; KIA; Marker of proliferation Ki-67; MIB 1; MIB; MKI67; PPP1R105; Proliferation marker protein Ki-67; Proliferation related Ki 67 antigen ; Protein phosphatase 1 regulatory subunit 105; RP11-380J17.2
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46013
-
Expression Region
2891-3256aa
-
Molecular Weight
56.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ki67, also known as MKI67, is a nuclear protein that serves as a marker for cellular proliferation and is widely used in cancer research and diagnostics. Discovered in the late 1980s, Ki67 is expressed during all active phases of the cell cycle (excluding the resting phase, G0), making it a reliable indicator of cell proliferation. Its relevance in oncology is underscored by its correlation with tumor aggressiveness, growth rate, and patient prognosis, particularly in various malignancies, such as breast, lung, and colorectal cancers. The study of Ki67 has evolved to include the exploration of its role in tumor biology and potential therapeutic implications. Recombinant Ki67/MKI67 proteins are generated to facilitate research on its functional properties and interactions within the cell. These recombinant proteins are valuable tools for investigating the molecular mechanisms underlying cancer cell proliferation and for identifying potential therapeutic targets. Additionally, the creation of specific antibodies against Ki67 helps in developing standardized assays for diagnostic purposes. The ongoing research aims to elucidate the complex regulatory networks involving Ki67 and to further understand its role in cancer progression, ultimately contributing to better diagnostic and treatment strategies. The importance of Ki67 in both basic research and clinical settings highlights its potential as a key biomarker in personalized medicine, guiding treatment decisions based on the proliferative activity of tumors.
